Edgewise Therapeutics Q2 2024 net loss $31.5M; cash $511.8M; EDG-7500 Phase 1 complete

Edgewise Therapeutics, Inc.

2024-Q2 EPS reported -$0.66

Net loss of $31.5M ($0.34 per share) vs $28.5M in prior quarter; no product revenue.
Cash and marketable securities $511.8M as of June 30, 2024.
Completed Phase 1 SAD/MAD trial of EDG-7500 in healthy volunteers; Phase 2 CIRRUS-HCM enrolling.
Sevasemten: CANYON Phase 2 data in Becker expected Q4 2024; GRAND CANYON pivotal cohort ongoing.
LYNX Phase 2 in Duchenne data expected Q4 2024; Phase 3 planned H1 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.